Kymera, rais­ing $173M+, be­comes the 48th biotech IPO of the year as 2020 sur­pass­es 2019

Yet an­oth­er biotech will hit Nas­daq on Fri­day, and this one marks a mile­stone for 2020.

Cam­bridge, MA-based Kymera has priced its IPO, an­nounc­ing a pub­lic price of $20 per share and $173.7 mil­lion raise. That’s up­sized from an ini­tial range of $16 to $18 per share, and would give the com­pa­ny a mar­ket val­ue north of $900 mil­lion.

The an­nounce­ment marks the 48th biotech IPO to go pub­lic this year, sur­pass­ing the to­tal from all of 2019, ac­cord­ing to in­vest­ment an­a­lyst Brad Lon­car. Kymera’s tick­er will be $KYMR.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER